Related references
Note: Only part of the references are listed.The Rotterdam Study: 2012 objectives and design update
Albert Hofman et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2011)
Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis
J. P. Greving et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease A Cost-Effectiveness Analysis
Crystal M. Smith-Spangler et al.
ANNALS OF INTERNAL MEDICINE (2010)
Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease
Rodney A. Hayward et al.
ANNALS OF INTERNAL MEDICINE (2010)
Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden
Janne A. Martikainen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Uncertainty and Patient Heterogeneity in Medical Decision Models
Bas Groot Koerkamp et al.
MEDICAL DECISION MAKING (2010)
Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease
Kirsten Bibbins-Domingo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Comparative Effectiveness of Heart Disease Prevention and Treatment Strategies
Thomas E. Kottke et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2009)
Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
Mark J. Pletcher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Economic Evaluation of Atorvastatin for Prevention of Recurrent Stroke Based on the SPARCL Trial
Thitima Kongnakorn et al.
VALUE IN HEALTH (2009)
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
J. J. Brugts et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands
Monique A. M. Jacobs-van der Bruggen et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2008)
Discounting in economic evaluations: Stepping forward towards optimal decision rules
Hugh Gravelle et al.
HEALTH ECONOMICS (2007)
A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease
S. Roze et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis
Thomas A. Gaziano et al.
LANCET (2006)
Effects of statins beyond lipid lowering: Potential for clinical benefits
K Almuti et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2006)
Statin safety: A systematic review
M Law et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: A cost-utility analysis
M Pignone et al.
ANNALS OF INTERNAL MEDICINE (2006)
Apparent and internal validity of a Monte Carlo-Markov model for cardiovascular disease in a cohort follow-up study
RL Nijhuis et al.
MEDICAL DECISION MAKING (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk
CJL Murray et al.
LANCET (2003)
Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe
ML Bots et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2002)
Share Paper
